Arcus Biosciences’ Post

Check out the newly published paper "SHP2 Inhibition Displays Efficacy as a Monotherapy and in Combination with JAK2 Inhibition in Preclinical Models of Myeloproliferative Neoplasms" This research demonstrates promising results in the use of SHP2 inhibitors, both as a standalone treatment and in combination with JAK2 inhibition, in preclinical models of myeloproliferative neoplasms. 🧬💊 This marks a significant step forward in our understanding of potential therapeutic strategies for these challenging conditions. The publication is now available, and I encourage everyone interested in the field to explore the details here: DOI: 10.1002/ajh.27282

> The pace of development in oligonucleotide therapeutics has accelerated in recent years, with a total of 18 drugs approved to date in the US and more than 1,000 in the pipeline – including clinical trials for major diseases such as Alzheimer’s. > We're excited to share an in-depth application note 𝗧𝗮𝗿𝗴𝗲𝘁𝗶𝗻𝗴 𝗼𝗳 𝗢𝗹𝗶𝗴𝗼𝗻𝘂𝗰𝗹𝗲𝗼𝘁𝗶𝗱𝗲 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀. It reviews promising lipid conjugation techniques and nanocarriers in preclinical development as well as approved oligonucleotide therapeutics. ⬇Download now: https://okt.to/qPfKb6 #AppNote #oligonucleotide #ResearchChemicals #ScienceForASaferWorld

> The pace of development in oligonucleotide therapeutics has accelerated in recent years, with a total of 18 drugs approved to date in the US and more than 1,000 in the pipeline – including clinical trials for major diseases such as Alzheimer’s. > We're excited to share an in-depth application note 𝗧𝗮𝗿𝗴𝗲𝘁𝗶𝗻𝗴 𝗼𝗳 𝗢𝗹𝗶𝗴𝗼𝗻𝘂𝗰𝗹𝗲𝗼𝘁𝗶𝗱𝗲 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀. It reviews promising lipid conjugation techniques and nanocarriers in preclinical development as well as approved oligonucleotide therapeutics. ⬇Download now: https://okt.to/2mXDUF #AppNote #oligonucleotide #ResearchChemicals #ScienceForASaferWorld

> The pace of development in oligonucleotide therapeutics has accelerated in recent years, with a total of 18 drugs approved to date in the US and more than 1,000 in the pipeline – including clinical trials for major diseases such as Alzheimer’s. > I have written an in-depth application note, investigating cutting-edge techniques for 𝗧𝗮𝗿𝗴𝗲𝘁𝗶𝗻𝗴 𝗼𝗳 𝗢𝗹𝗶𝗴𝗼𝗻𝘂𝗰𝗹𝗲𝗼𝘁𝗶𝗱𝗲 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀. It reviews promising lipid conjugation techniques and nanocarriers in preclinical development as well as approved oligonucleotide therapeutics. ⬇Download now: https://okt.to/s7PwAR #AppNote #oligonucleotide #ResearchChemicals #ScienceForASaferWorld

✨Get our new App Note: Targeting of Oligonucleotide Therapeutics https://okt.to/okuSU1 > The pace of development in #oligonucleotide therapeutics has accelerated in recent years, with a total of 18 drugs approved to date in the US and more than 1,000 in the pipeline – including clinical trials for major diseases such as Alzheimer’s. > This app note reviews promising lipid conjugation techniques and nanocarriers in preclinical development as well as approved oligonucleotide therapeutics. #AppNote #oligonucleotide #ResearchChemicals #ScienceForASaferWorld

Medicenna Therapeutics Corp. secured a patent that protects a new method for enhancing fitness, survival, and proliferation of cancer-killing effector T cells and NK cells. The recently granted patent strengthens Medicenna's position, expanding its Superkine toolbox to further advance its contributions to the field of hashtag cancer immunotherapy . Merck currently leads the space with more than 35% of its patents granted. 💡 GlobalData's Patent module delivers specialized expertise in the pharmaceutical industry, harnessing our unique data, insights, and analytics. Our tailored approach and deliverables empower you with comprehensive answers to your specific patent-related questions. Learn more by contacting me today! #cancerimmunotherapy #patents #lifesciences #biotechnology #immunooncology

> The pace of development in oligonucleotide therapeutics has accelerated in recent years, with a total of 18 drugs approved to date in the US and more than 1,000 in the pipeline – including clinical trials for major diseases such as Alzheimer’s. > We're excited to share an in-depth application note 𝗧𝗮𝗿𝗴𝗲𝘁𝗶𝗻𝗴 𝗼𝗳 𝗢𝗹𝗶𝗴𝗼𝗻𝘂𝗰𝗹𝗲𝗼𝘁𝗶𝗱𝗲 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀. It reviews promising lipid conjugation techniques and nanocarriers in preclinical development as well as approved oligonucleotide therapeutics. ⬇Download now: https://okt.to/IPiJLq #AppNote #oligonucleotide #ResearchChemicals #ScienceForASaferWorld

Get our new application note today: 𝗧𝗮𝗿𝗴𝗲𝘁𝗶𝗻𝗴 𝗼𝗳 𝗢𝗹𝗶𝗴𝗼𝗻𝘂𝗰𝗹𝗲𝗼𝘁𝗶𝗱𝗲 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 https://okt.to/S9rJDn This application note reviews promising lipid conjugation techniques and nanocarriers in preclinical development as well as approved oligonucleotide therapeutics. Download it to learn more. #AppNote #oligonucleotide #ResearchChemicals #ScienceForASaferWorld

Get our latest application note to learn more about groundbreaking conjugation and nano-delivery chemistry techniques in oligonucleotide therapeutics research. https://okt.to/Z9MPXG The pace of development in oligonucleotide therapeutics has accelerated in recent years, with a total of 18 drugs approved to date in the US and more than 1,000 in the pipeline – including clinical trials for major diseases such as Alzheimer’s. This in-depth application note reviews promising lipid conjugation techniques and nanocarriers in preclinical development as well as approved oligonucleotide therapeutics. Download now! #AppNote #oligonucleotide #ResearchChemicals #ScienceForASaferWorld

Peptide therapeutics are gaining popularity because of developments in biotechnology and bioengineering, including cancer diagnosis and treatment, antibiotic drug development, and new vaccines. https://lnkd.in/gxS2gsZZ This application note describes the ability to perform direct scale up from analytical PLRP-S 4.6 × 250 mm, 8 µm columns to larger scale preparative PLRP-S 21.2 × 250 mm, 8 µm columns. The amino acid sequence of synthetic GLP-1 (7-36) amide: H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-NH2 The characterization of the final product was confirmed using an 6545XT LC/Q-TOF.